NCT06457919 - A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Prostate Cancer

Interventions

DRUG

Tinengotinib

Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.

DRUG

abiraterone acetate with prednisone

Abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID)

DRUG

Enzalutamide

Enzalutamide 160 mg PO QD

Trial Locations (11)

10032

RECRUITING

Columbia University, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

19107

NOT_YET_RECRUITING

Thomas Jefferson University Hospital, Philadelphia

27710

RECRUITING

Duke University, Durham

97239

RECRUITING

Oregon Health & Science University, Portland

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

TransThera Sciences

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER